Verapamil in acute myocardial infarction. The rationales of the VAMI and DAVIT III trials.
Verapamil is well tolerated in patients with stable and unstable angina pectoris, as well as in patients with threatened infarction. No data exist documenting verapamil to be inferior to beta-blockers in these stages of coronary heart diseases. In the pre-thrombolytic era i.v. intervention with verapamil did not add any benefit in the early phase of AMI. However, a retrospective analysis suggests the hypothesis that i.v. verapamil given in combination with thrombolysis may improve the prognosis, and an ongoing study (VAMI trial) examines this hypothesis. When given in the late in-hospital phase of AMI to patients without heart failure verapamil significantly reduces mortality and morbidity. When given in the late in-hospital phase to patients with heart failure verapamil did not cause the course or prognosis to deteriorate and might even improve it in patients with residual ischaemia, especially when given in combination with an ACE-inhibitors. A planned study (DAVIT III study) has to confirm these preliminary data.
Jespersen
C M
CM
Department of Cardiovascular Medicine Y, Bispebjerg Hospital, Copenhagen, Denmark.
D000208:Acute Disease; D000787:Angina Pectoris / Q000188:drug therapy / Q000401:mortality; D000789:Angina, Unstable / Q000188:drug therapy / Q000401:mortality; D002121:Calcium Channel Blockers / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000401:mortality; D014700:Verapamil / Q000009:adverse effects / Q000627:therapeutic use*
D002121:Calcium Channel Blockers; D005343:Fibrinolytic Agents; D014700:Verapamil